TRUNCATED MEMAPSIN 2 COMPOSITIONS AND TREATMENTS
First Claim
Patent Images
1. A method of reducing memapsin 2 β
- -secretase activity to treat a disease associated with memapsin 2 β
-secretase activity in a subject in need of such treatment, the method comprising administering to said subject an effective amount of a truncated memapsin 2 protein, and wherein said truncated memapsin 2 protein consists of amino acids 63-454 of FIG. 4, optionally containing at least one conservative amino acid substitution.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides novel methods of reducing memapsin 2 β-secretase activity in a subject, decreasing levels of β-amyloid peptide in the brain of a subject, treating Alzheimer'"'"'s disease and/or reducing the size and/or number of β-amyloid plaques in the brain of a subject. The methods may include the step of administering an effective amount of truncated memapsin 2 protein, anti-truncated memapsin 2 antibody, and/or nucleic acid encoding a truncated memapsin 2 protein or anti-truncated memapsin 2 antibody. The present invention also provides related pharmaceutical compositions and uses thereof.
87 Citations
22 Claims
-
1. A method of reducing memapsin 2 β
- -secretase activity to treat a disease associated with memapsin 2 β
-secretase activity in a subject in need of such treatment, the method comprising administering to said subject an effective amount of a truncated memapsin 2 protein, and wherein said truncated memapsin 2 protein consists of amino acids 63-454 ofFIG. 4 , optionally containing at least one conservative amino acid substitution. - View Dependent Claims (2, 3, 4, 10)
- -secretase activity to treat a disease associated with memapsin 2 β
-
5-9. -9. (canceled)
-
11. A method of decreasing levels of β
- -amyloid peptide in the brain of a subject, said method comprising administering to said subject an effective amount of a truncated memapsin 2 protein, and wherein said truncated memapsin 2 protein consists of amino acids 63-454 of
FIG. 4 , optionally containing at least one conservative amino acid substitution, and said truncated memapsin 2 protein reduces memapsin 2 β
-secretase activity in said subject.
- -amyloid peptide in the brain of a subject, said method comprising administering to said subject an effective amount of a truncated memapsin 2 protein, and wherein said truncated memapsin 2 protein consists of amino acids 63-454 of
-
12. A method of reducing the size or number of β
- -amyloid plaques in the brain of said subject, said method comprising administering to said subject an effective amount of a truncated memapsin 2 protein, and wherein said truncated memapsin 2 protein consists of amino acids 63-454 of
FIG. 4 , optionally containing at least one conservative amino acid substitution, and said truncated memapsin 2 protein reduces memapsin 2 β
-secretase activity in said subject.
- -amyloid plaques in the brain of said subject, said method comprising administering to said subject an effective amount of a truncated memapsin 2 protein, and wherein said truncated memapsin 2 protein consists of amino acids 63-454 of
-
13. A method of treating Alzheimer'"'"'s disease in a patient in need of such treatment, said method comprising administering to said subject an effective amount of a truncated memapsin 2 protein, and wherein said truncated memapsin 2 protein consists of amino acids 63-454 of
FIG. 4 , optionally containing at least one conservative amino acid substitution, and said truncated memapsin 2 protein reduces memapsin 2 β- -secretase activity in said subject.
-
14. An antibody specifically immunoreactive with a truncated memapsin 2 protein, and wherein said truncated memapsin 2 protein consists of amino acids 63-454 of
FIG. 4 , optionally containing at least one conservative amino acid substitution, and said antibody reduces memapsin 2 β- -secretase activity.
- View Dependent Claims (15, 16, 17, 18, 19)
-
20. A pharmaceutical composition comprising a truncated memapsin 2 and a pharmaceutically acceptable adjuvant, wherein said truncated memapsin 2 protein consists of amino acids 63-454 of
FIG. 4 , optionally containing at least one conservative amino acid substitution.
-
21. A pharmaceutical composition comprising a nucleic acid encoding a truncated memapsin 2 and a pharmaceutically acceptable excipient, wherein said truncated memapsin 2 protein consists of amino acids 63-454 of
FIG. 4 , optionally containing at least one conservative amino acid substitution.
-
22. An antibody specifically immunoreactive with a truncated memapsin 2 protein, and wherein said truncated memapsin 2 protein consists of amino acids 63-454 of
FIG. 4 , optionally containing at least one conservative amino acid substitution, and said antibody reduces Aβ- production.
Specification